Zeitlin PL

Idioma: Ingles.
Referencias bibliográficas: 19
Paginas: 287-293
Archivo PDF: 228.14 Kb.

FRAGMENTO

Sin resumen.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43:343-373. Epub 2013/12/18. doi: 10.1183/09031936.00202013. PubMed PMID: 24337046.

2. McGregor MC, Krings JG, Nair P, Castro M. Role of biologics in asthma. Am J Respir Crit Care Med. 2019;199:433-445. Epub 2018/12/12. doi: 10.1164/rccm.201810-1944CI. PubMed PMID: 30525902.

3. Israel E, Reddel HK. Severe and Difficult-to-Treat Asthma in Adults. N Engl J Med. 2017;377:965-976. Epub 2017/09/07. doi: 10.1056/ NEJMra1608969. PubMed PMID: 28877019.

4. Esquivel A, Busse WW, Calatroni A, Togias AG, Grindle KG, Bochkov YA, et al. Effects of Omalizumab on Rhinovirus Infections, Illnesses, and Exacerbations of Asthma. Am J Respir Crit Care Med. 2017;196:985- 992. Epub 2017/06/14. doi: 10.1164/rccm.201701-0120OC. PubMed PMID: 28608756; PMCID: PMC5649984.

5. Busse WW, Morgan WJ, Gergen PJ, Mitchell HE, Gern JE, Liu AH, et al. Randomized trial of omalizumab (anti-IgE) for asthma in innercity children. N Engl J Med. 2011;364:1005-1015. Epub 2011/03/18. doi: 10.1056/NEJMoa1009705. PubMed PMID: 21410369; PMCID: PMC3093964.

6. Teach SJ, Gergen PJ, Szefler SJ, Mitchell HE, Calatroni A, Wildfire J, et al. Seasonal risk factors for asthma exacerbations among innercity children. J Allergy Clin Immunol. 2015;135:1465-1473 e5. Epub 2015/03/22. doi: 10.1016/j.jaci.2014.12.1942. PubMed PMID: 25794658; PMCID: PMC4461505.

7. Hanania NA, Wenzel S, Rosen K, Hsieh HJ, Mosesova S, Choy DF, et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med. 2013;187:804-811. Epub 2013/03/09. doi: 10.1164/rccm.201208- 1414OC. PubMed PMID: 23471469.

8. Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med. 2009;360:973-984. Epub 2009/03/07. doi: 10.1056/ NEJMoa0808991. PubMed PMID: 19264686; PMCID: PMC3992367.

9. Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380:651-659. Epub 2012/08/21. doi: 10.1016/S0140-6736(12)60988-X. PubMed PMID: 22901886.

10. Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371:1198-1207. Epub 2014/09/10. doi: 10.1056/NEJMoa1403290. PubMed PMID: 25199059.

11. Castro M, Zangrilli J, Wechsler ME, Bateman ED, Brusselle GG, Bardin P, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, doubleblind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015;3:355-366. Epub 2015/03/05. doi: 10.1016/S2213-2600(15)00042- 9. PubMed PMID: 25736990.

12. Castro M, Zangrilli J, Wechsler ME. Corrections. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015;3:e15. Epub 2015/04/22. doi: 10.1016/S2213-2600(15)00119-8. PubMed PMID: 25890659.

13. Corren J, Weinstein S, Janka L, Zangrilli J, Garin M. Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts. Chest. 2016;150:799-810. Epub 2016/03/29. doi: 10.1016/j.chest.2016.03.018. PubMed PMID: 27018175.

14. Bleecker ER, FitzGerald JM, Chanez P, Papi A, Weinstein SF, Barker P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;388:2115-2127. Epub 2016/09/10. doi: 10.1016/S0140-6736(16)31324-1. PubMed PMID: 27609408.

15. FitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, et al. Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388:2128-2141. Epub 2016/09/10. doi: 10.1016/S0140-6736(16)31322-8. PubMed PMID: 27609406.

16. Nair P, Wenzel S, Rabe KF, Bourdin A, Lugogo NL, Kuna P, et al. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N Engl J Med. 2017;376:2448-2458. Epub 2017/05/23. doi: 10.1056/ NEJMoa1703501. PubMed PMID: 28530840.

17. Zeitlin PL, Leong M, Cole J, Mallory RM, Shih VH, Olsson RF, et al. Benralizumab does not impair antibody response to seasonal influenza vaccination in adolescent and young adult patients with moderate to severe asthma: results from the Phase IIIb ALIZE trial. J Asthma Allergy. 2018;11:181-92. Epub 2018/12/05. doi: 10.2147/JAA.S172338. PubMed PMID: 30510434; PMCID: PMC6248228.

18. Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378:2486-2496. Epub 2018/05/22. doi: 10.1056/NEJMoa1804092. PubMed PMID: 29782217.

19. Rabe KF, Nair P, Brusselle G, Maspero JF, Castro M, Sher L, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018;378:2475-2485. Epub 2018/05/22. doi: 10.1056/NEJMoa1804093. PubMed PMID: 29782224.